Free Trial
NASDAQ:ADAG

Adagene (ADAG) Stock Price, News & Analysis

Adagene logo
$2.85
-0.30 (-9.52%)
(As of 05:16 PM ET)

About Adagene Stock (NASDAQ:ADAG)

Key Stats

Today's Range
$2.60
$3.15
50-Day Range
$2.12
$3.49
52-Week Range
$1.31
$4.38
Volume
67,466 shs
Average Volume
69,074 shs
Market Capitalization
$126.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Adagene Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
65th Percentile Overall Score

ADAG MarketRank™: 

Adagene scored higher than 65% of companies evaluated by MarketBeat, and ranked 423rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Adagene has only been the subject of 1 research reports in the past 90 days.

  • Read more about Adagene's stock forecast and price target.
  • Earnings Growth

    Earnings for Adagene are expected to decrease in the coming year, from ($0.75) to ($1.33) per share.

  • Price to Book Value per Share Ratio

    Adagene has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.06% of the float of Adagene has been sold short.
  • Short Interest Ratio / Days to Cover

    Adagene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adagene has recently decreased by 30.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Adagene does not currently pay a dividend.

  • Dividend Growth

    Adagene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.06% of the float of Adagene has been sold short.
  • Short Interest Ratio / Days to Cover

    Adagene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adagene has recently decreased by 30.74%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Adagene has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Adagene this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Adagene to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adagene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.51% of the stock of Adagene is held by institutions.

  • Read more about Adagene's insider trading history.
Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Stock News Headlines

Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7%
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Adagene And 2 Other US Penny Stocks To Consider
See More Headlines

ADAG Stock Analysis - Frequently Asked Questions

Adagene's stock was trading at $1.9314 at the beginning of the year. Since then, ADAG stock has increased by 47.6% and is now trading at $2.85.
View the best growth stocks for 2024 here
.

Adagene (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager.

Adagene's top institutional investors include Catalina Capital Group LLC (0.03%).

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADAG
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+75.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$815,746.00
Book Value
$1.61 per share

Miscellaneous

Free Float
34,886,000
Market Cap
$126.17 million
Optionable
Not Optionable
Beta
0.65
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:ADAG) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners